2013 Fiscal Year Final Research Report
Characterization and clinical application of endogenous Alzheimer's disease-suppressing factor
Project/Area Number |
23390059
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General pharmacology
|
Research Institution | Tokyo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
IWAMOTO Toshihiko 東京医科大学, 医学部, 兼任教授 (10246168)
UMAHARA Takahiko 東京医科大学, 医学部, 准教授 (70266477)
|
Project Period (FY) |
2011-04-01 – 2014-03-31
|
Keywords | アルツハイマー病 / 神経細胞死 / ヒューマニン |
Research Abstract |
A new Alzheimer's disease (AD)-suppressive factor EH has been biologically examined. First, it was found that EH concentration in the cerebrospinal fluid is 1-5nM in humans. Second, intraperitoneal administration of EH ameliorates dementia of mice, caused by scopolamine, a muscarinic acetylcholine receptor blocker.. Combined with foregoing findings, these results suggest that EH, rather than Humanin, plays a central role in vivo as an AD-suppressive factor.. Furthermore, EH concentrations in the cerebrospinal fluids of AD patients appear to be lower than those of normal controls. Finally, it was found that EHIbeta inhibits secretion of into extracellular space and EHIsigma is secreted into the extracellular space and inhibits EH activity.
|
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin2011
Author(s)
Rossini L, Hashimoto Y, Suzuki H, Kurita M, Gianfriddo M, Scali C, Roncarati R, Franceschini D, Pollio G, Trabalzini L, Terstappen GC, Matsuoka M, Caricasole A
-
Journal Title
FASEB J
Volume: 25
Pages: 1983-2000
-
-
-